Zobrazeno 1 - 10
of 55
pro vyhledávání: '"Hiraku Fukushima"'
Autor:
Yasuyuki Kawamoto, Yoshito Komatsu, Satoshi Yuki, Kentaro Sawada, Tetsuhito Muranaka, Kazuaki Harada, Hiroshi Nakatsumi, Hiraku Fukushima, Atsushi Ishiguro, Masayoshi Dazai, Kazuteru Hatanaka, Michio Nakamura, Ichiro Iwanaga, Minoru Uebayashi, Susumu Sogabe, Yoshimitsu Kobayashi, Takuto Miyagishima, Kota Ono, Naoya Sakamoto, Yuh Sakata
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-6 (2017)
Abstract Background In Japan, S-1 plus cisplatin (SP) regimen has become a standard therapy for patients with advanced gastric cancer. Moreover, the S-1 plus oxaliplatin regimen is now a standard treatment. Nab-paclitaxel was developed for chemothera
Externí odkaz:
https://doaj.org/article/5eb50e1555324189bdb9aa9a907bc4f0
Autor:
Hitoshi Yokoyama, Yuichi Shimizu, Takanori Aoki, Masato Kawakami, Hiroshi Nishihara, Kimimoto Nagashima, Hideyuki Hayashi, Hiraku Fukushima, Tsuyoshi Shimamura, Yasushi Danjo, Naoki Asakage, Hiromi Ono, Mikio Okamura, Mitsuo Kusano, Haruyuki Yoshida
Publikováno v:
Journal of Gastroenterology and Hepatology Research. 9:3320-3324
Autor:
Satoshi Yuki, Ayana Endo, Taichi Murai, Shuji Nishikawa, Ayane Oba, Takahiko Kudo, Kazufumi Itaya, Yuji Ono, Yuta Koike, Tetsuhito Muranaka, Michio Nakamura, Yoshito Komatsu, Takayuki Sone, Atsushi Ishiguro, Masataka Yagisawa, Atsushi Nagasaka, Hiraku Fukushima, Kota Ono, Chika Matsuda, Yoko Tsukuda
Publikováno v:
The Oncologist
This study is an evaluation of the effect of gastrointestinal cancer chemotherapy with short‐term periodic steroid premedication on bone metabolism. Primary endpoints were changes in bone mineral densities and metabolic bone turnover 16 weeks after
Autor:
Hiromi, Ono, Mitsuo, Kusano, Masashi, Nihei, Hideyuki, Hayashi, Hiraku, Fukushima, Masato, Kawakami, Yasushi, Danjo, Kimimoto, Nagashima, Yuichi, Shimizu, Futoshi, Kawamata, Shohei, Honda, Tsuyoshi, Shimamura, Hiroshi, Nishihara
Publikováno v:
Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology. 115(4)
When injected, indocyanine green (ICG) immediately combines with lipoproteins to fluoresce. Here, we studied whether ICG fluorescence is effective for endoscopic marking in gastric cancer surgery using a photodynamic eye (PDE) camera and fluorescent
Autor:
Masayoshi Dazai, Hiraku Fukushima, Yuh Sakata, Satoshi Yuki, Yasuyuki Kawamoto, Kentaro Sawada, Kota Ono, Yoshimitsu Kobayashi, Tetsuhito Muranaka, Minoru Uebayashi, Kazuteru Hatanaka, Kazuaki Harada, Naoya Sakamoto, Hiroshi Nakatsumi, Susumu Sogabe, Ichiro Iwanaga, Yoshito Komatsu, Takuto Miyagishima, Atsushi Ishiguro, Michio Nakamura
Publikováno v:
BMC Cancer
BMC Cancer, Vol 17, Iss 1, Pp 1-6 (2017)
BMC Cancer, Vol 17, Iss 1, Pp 1-6 (2017)
Background In Japan, S-1 plus cisplatin (SP) regimen has become a standard therapy for patients with advanced gastric cancer. Moreover, the S-1 plus oxaliplatin regimen is now a standard treatment. Nab-paclitaxel was developed for chemotherapy of gas
Autor:
Hiroyuki Masuko, Hiraku Fukushima, Tomohisa Furuhata, Yoshito Komatsu, Kazunori Eto, Mineo Kudo, Koji Oba, Hitoshi Shibuya, Yasuo Takahashi, Hiroshi Isobe, Yasuyuki Kawamoto, Junta Nakajima, Michio Nakamura, Miki Tateyama, Satoshi Yuki, Shinya Minami, Takuto Miyagishima, Kazuaki Sasaki, Kenji Okita, Yoshinobu Ohsaki, Ryoji Yokoyama, Ichiro Iwanaga
Publikováno v:
Cancer Science
The purpose of this study is to compare the efficacy of a single administration of dexamethasone (DEX) on day 1 against DEX administration on days 1–3 in combination with palonosetron (PALO), a second-generation 5-HT3 receptor antagonist, for chemo
Autor:
Yoshito Komatsu, Satoshi Yuki, Hiraku Fukushima, Ichiro Iwanaga, Hiroshi Nakatsumi, Yuh Sakata, Mineo Kudo, Yoshimitsu Kobayashi, Takashi Meguro, Takuto Miyagishima, Kazuteru Hatanaka, Susumu Sogabe, Miki Tateyama, Masaki Munakata, Michio Nakamura
Publikováno v:
Acta Oncologica. 51:867-872
Background. In Japan, a study comparing the effectiveness and safety of irinotecan plus S-1 (IRIS) with those of a combination of 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) as second-line treatment in patients with advanced or recurrent col
Autor:
Atsushi Ochiai, Hideaki Bando, Atsushi Ohtsu, Naomi Ogasawara, Takayuki Yoshino, Hiroyasu Esumi, Motohiro Kojima, Katsuya Tsuchihara, Hiraku Fukushima
Publikováno v:
Japanese Journal of Clinical Oncology. 41:239-244
Objective: The concordance of KRAS mutation detection between the amplification refractory mutation system‐Scorpion assay and direct sequencing was evaluated with clinically available formalin-fixed, paraffin-embedded specimens of metastatic colore
Autor:
Naoya Sakamoto, Takaya Kusumi, Satoshi Yuki, Michio Nakamura, Miki Tateyama, Hiraku Fukushima, Susumu Sogabe, Fumiyasu Yamamoto, Ichiro Iwanaga, Yasushi Tsuji, Kazuhiro Iwai, Yoshito Komatsu, Yuh Sakata, Koji Oba, Jun Konno, Hiroyuki Okuda, Minoru Uebayashi, Kazuteru Hatanaka, Yoshimitsu Kobayashi, Manabu Onodera, Takahide Sasaki, Riichiro Abe, Takuto Miyagishima
Publikováno v:
Future oncology (London, England). 11(4)
ABSTRACT Aim: We planned a randomized, open-label trial to evaluate differences between pre-emptive and reactive skin treatment for panitumumab (Pmab)-associated skin toxicities in Japanese patients with metastatic colorectal cancer. Patients & metho
Publikováno v:
Nihon rinsho. Japanese journal of clinical medicine. 72(1)
I explain an outline of the molecular target of new drugs for colorectal cancer. First, regorafenib is an orally active, multikinase inhibitor. Second, as angiogenesis inhibitors, aflibercept and ramucirumab. Aflibercept is the second anti-angiogenic